Hao K, Paik AJ, Han LH, Makary MS. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J Radiol 2024; 16(10): 512-527 [PMID: 39494134 DOI: 10.4329/wjr.v16.i10.512]
Corresponding Author of This Article
Mina S Makary, MD, Associate Professor, Attending Doctor, Director, Department of Radiology, The Ohio State University Medical Center, 395 West 12th Avenue, Columbus, OH 43210, United States. mina.makary@osumc.edu
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Radiol. Oct 28, 2024; 16(10): 512-527 Published online Oct 28, 2024. doi: 10.4329/wjr.v16.i10.512
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma
Kelly Hao, Andrew J Paik, Lauren H Han, Mina S Makary
Kelly Hao, Andrew J Paik, Lauren H Han, College of Medicine, The Ohio State University, Columbus, OH 43210, United States
Mina S Makary, Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, United States
Author contributions: All authors contributed meaningfully to the preparation of the manuscript. Hao K and Makary MS conceptualized and designed the study; Hao K, Paik AJ, and Han LH conducted the literature review, did the analysis, drafted the original manuscript, and made critical revisions; Makary MS supervised the review, advised the review design, and critically revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina S Makary, MD, Associate Professor, Attending Doctor, Director, Department of Radiology, The Ohio State University Medical Center, 395 West 12th Avenue, Columbus, OH 43210, United States. mina.makary@osumc.edu
Received: June 3, 2024 Revised: October 14, 2024 Accepted: October 21, 2024 Published online: October 28, 2024 Processing time: 147 Days and 4.9 Hours
Abstract
As the third leading cause of cancer-related deaths worldwide, hepatocellular carcinoma (HCC) represents a significant global health challenge. This paper provides an introduction and comprehensive review of transarterial radioembolization (TARE) with Yttrium-90 (Y90), a widely performed transcatheter procedure for HCC patients who are not suitable candidates for surgery. TARE involves the targeted delivery of radioactive microspheres to liver tumors, offering a promising treatment option for managing HCC across various stages of the disease. By evaluating Y90 TARE outcomes across early, intermediate, and advanced stages of HCC, the review aims to present a thorough understanding of its efficacy and safety. Additionally, this paper highlights future research directions focusing on the potential of combination therapies with systemic and immunotherapies, as well as personalized treatments. The exploration of these innovative approaches aims to improve treatment outcomes, reduce adverse events, and provide new therapeutic opportunities for HCC patients. The review underscores the importance of ongoing research and clinical trials to optimize TARE further and integrate it into comprehensive HCC treatment paradigms.
Core Tip: This comprehensive review explores Yttrium-90 transarterial radioembolization (TARE) as an effective locoregional therapy for hepatocellular carcinoma across various stages. It compares TARE’s advantages over other locoregional treatments and systemic therapies, emphasizing its role in enhancing treatment efficacy and patient outcomes. The potential of TARE in combination with systemic and immunotherapies is highlighted, pointing towards a future of precision medicine through personalized treatments. This comprehensive review aims to elucidate TARE’s efficacy, safety, and evolving role in hepatocellular carcinoma management. By addressing emerging findings and new methodologies, we aim to advance the understanding and application of this promising technique in interventional radiology.
